Cellino's iPSC Manufacturing Technology Receives FDA Advanced Manufacturing Technology (AMT) Designation
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Cellino, a leader in advanced biomanufacturing, today announced that its optical biomanufacturing technology for generating induced pluripotent stem cells (iPSCs) has received the FDA's Advanced Manufacturing Technology (AMT) designation from the Center for Biologics Evaluation and Research (CBER). This prestigious designation highlights the transformative potential of Cellino's automated technology for scaling up high-quality iPSCs to industrialize next-generation regenerative therapies.
The FDA encourages the adoption of advanced manufacturing technologies (AMTs) that improve manufacturing reliability, product quality, and production scale. The AMT designation accelerates timelines for therapies manufactured using Cellino's optical biomanufacturing technology, offering higher priority within the FDA, along with earlier and more frequent interactions during Investigational New Drug (IND), New Drug Application (NDA), and Biologics License Application (BLA) processes for a faster path to market.
'We are honored to receive the AMT designation for our proprietary technology stack,' said Nabiha Saklayen, Ph.D., CEO and Co-Founder of Cellino. 'This recognition affirms our commitment to revolutionizing the production of patient-specific iPSCs, enabling faster and more consistent clinical and commercial-scale manufacturing. It's a pivotal moment in our mission to deliver personalized regenerative therapies that can scale globally, transforming healthcare for millions.'
Autologous iPSC manufacturing has long been one of the most complex challenges in biomanufacturing, involving labor-intensive processes like manual passaging and colony picking that only a limited number of experts worldwide can perform. These hurdles have slowed progress, preventing many therapeutic programs from advancing past early-phase clinical trials. Cellino's proprietary optical bioprocessing technology overcomes these challenges by introducing precision, reproducibility, and scalability, ensuring reliable, high-quality iPSC production for both clinical trials and commercial stages.
'This AMT designation underscores the scientific rigor and transformative potential of our technology,' said Marinna Madrid, Ph.D., Chief Product Officer and Co-Founder of Cellino. 'Automated, optical manufacturing is key to ensuring patient access to regenerative medicines. This milestone brings us closer to scaling therapies from Phase 1 through large-scale commercialization, aiming to address some of the world's most debilitating chronic degenerative diseases.'
Cellino intends to leverage the AMT designation to expedite the translation of personalized iPSC-derived therapies into clinical practice. With global chronic disease burdens rising and more than 100 million individuals in the U.S. alone who could potentially benefit from iPSC-derived therapies, Cellino's technology is poised to significantly expand patient access to next-generation living medicines.
For more information on the FDA's Advanced Manufacturing Technologies Designation Program, visit the FDA AMT Guidance.
About Cellino
Cellino is a leader in advanced biomanufacturing technology, committed to making personalized cell, tissue, and organ replacements a reality for patients around the world. Learn more at www.cellinobio.com and follow us on LinkedIn and X.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
20 minutes ago
- Business Wire
Wolters Kluwer executive delivers keynote on the future of integrated tech stacks and agentic AI at AICPA Engage 2025
MINNEAPOLIS--(BUSINESS WIRE)-- Wolters Kluwer Tax and Accounting (TAA) executive, Cathy Rowe, Senior Vice President and Segment Leader, U.S. Professional Market, delivered a compelling keynote address today at AICPA Engage 2025, held at the Aria Resort and Casino in Las Vegas. Her remarks focused on the accelerating pace of technological change and how integrated tech stacks and agentic AI are reshaping the accounting profession for audit and tax professionals. In her keynote, Rowe emphasized that the rate of technological change is now faster than ever, urging firms to embrace both sustaining and disruptive innovation. She shared insights from Wolters Kluwer's 'Future Ready Accountant' study, which found that 77% of firms experienced growth last year, yet 40% cited keeping up with new technology as their top challenge. Rowe highlighted that firms using fully integrated solutions reported revenue increases of 10% or more, underscoring the ROI of strategic tech investments. She outlined four key pillars for leveraging AI in modern firms: Data-Driven Firm Management – Using AI to generate real-time insights and automate reporting. Increased Efficiencies and Capacity – Streamlining workflows and optimizing staff allocation. Proactive Risk Management – Monitoring tax and audit data to identify and mitigate risks. Enhanced Client Service – Shifting from compliance to advisory roles through AI-driven insights and automation. A central theme of Rowe's address was the emergence of agentic AI—a transformative evolution from traditional automation to intelligent agents that act autonomously with human oversight. She explained how agentic AI spans four key categories: Taskers, Automators, Collaborators, and Orchestrators. These agents can classify documents, manage workflows, guide professionals through complex tasks, and even orchestrate entire audit or tax preparation processes. Crucially, this next-generation AI is made possible through open integration platforms, enabling firms of all sizes to benefit from seamless automation, data interoperability, and intelligent decision-making. 'Agentic AI is not just a buzzword—it's a strategic enabler,' Rowe stated. 'It empowers professionals to work at the top of their credentials, enhances client service, and creates competitive advantage. With open integration APIs, firms can build intelligent, responsive systems that adapt in real time.' Wolters Kluwer is actively advancing the integration of agentic AI across its suite of tax and accounting solutions as part of its long-term innovation strategy centered on firm intelligence. Building on more than a decade of AI investment, these enhancements will empower professionals to automate complex workflows, enhance decision-making, and deliver greater value to clients. Customers can expect to begin experiencing these next-generation capabilities in the near future, reinforcing Wolters Kluwer's commitment to helping firms stay future-ready. Rowe concluded by encouraging firms to assess their current workflows, evaluate integration opportunities, and invest in talent and change management to become truly future-ready. Professionals interested in learning how Wolters Kluwer can help them prepare for the future are encouraged to contact their sales representative. Interview Opportunity Media interested in scheduling an interview with Cathy Rowe may reach out to Shannon Wherry, Associate Director, External Communications at About Wolters Kluwer Wolters Kluwer (EURONEXT: WKL) is a global leader in information, software solutions and services for professionals in healthcare; tax and accounting; financial and corporate compliance; legal and regulatory; corporate performance and ESG. We help our customers make critical decisions every day by providing expert solutions that combine deep domain knowledge with technology and services. Wolters Kluwer reported 2024 annual revenues of €5.9 billion. The group serves customers in over 180 countries, maintains operations in over 40 countries, and employs approximately 21,600 people worldwide. The company is headquartered in Alphen aan den Rijn, the Netherlands. For more information, visit and follow us on LinkedIn, Facebook, YouTube and Instagram.
Health Line
21 minutes ago
- Health Line
Primary Progressive MS: Myths vs. Facts
Misconceptions about primary progressive multiple sclerosis (PPMS) are common, especially since the condition can look different for everyone. Knowing what's true (and what's not) can help you feel more informed and empowered. Primary progressive multiple sclerosis (PPMS) is a complex condition that looks different from person to person. Symptoms, experiences, and rates of progression can vary widely. Because PPMS isn't as well-known as other types of multiple sclerosis (MS), myths and misconceptions often fill the gaps. That can make it harder to find trustworthy answers when you're trying to learn more about the condition. Here, we break down some of the most common myths about PPMS and share the facts behind them. Myth#1: There will never be a cure for PPMS Fact: While there's no cure yet, treatment options are expanding, and research is ongoing. In 2017, the Food and Drug Administration (FDA) approved Ocrevus (ocrelizumab) as the first disease-modifying therapy (DMT) for PPMS. In 2024, a new formulation called ocrelizumab and hyaluronidase-ocsq (Ocrevus Zunovo), a subcutaneous injection administered twice a year, was approved. This new injection offers a quicker, approximately 10-minute administration alternative to the traditional intravenous infusion. Ocrevus and Ocrevus Zunovo are currently the only FDA-approved DMTs for PPMS. However, researchers are actively exploring new therapies. For instance, tolebrutinib, a Bruton's tyrosine kinase (BTK) inhibitor, is undergoing phase 3 trials to assess its potential in slowing PPMS progression. Additionally, scientists are investigating treatments aimed at repairing myelin, the protective sheath around nerves damaged in MS. One such study involves combining metformin, a common diabetes medication, with clemastine, an antihistamine, to promote myelin repair. Myelin repair is important because it may help restore nerve function and slow disease progression. Although a cure for PPMS has yet to be found, these developments reflect a growing commitment to improving treatment options and outcomes. Myth: PPMS primarily occurs in females Fact: PPMS affects people of all sexes at the same rate. While relapsing-remitting multiple sclerosis (RRMS) is more common in people assigned female at birth (AFAB), affecting them two to three times more often than those assigned male at birth (AMAB), PPMS affects AFABs and AMABs in roughly equal numbers. It's important not to assume the type of MS based solely on sex. Regardless of gender, if you experience symptoms suggestive of MS, consult a healthcare professional for an accurate diagnosis. Myth: PPMS is an older person's disease Fact: PPMS typically begins in mid-adulthood, not old age. While PPMS tends to have a later onset than other forms of MS, it doesn't primarily affect older adults. On average, people with PPMS start experiencing symptoms around the age of 40. Myth: A PPMS diagnosis means you'll be disabled Fact: Disability progression in PPMS varies widely, and many people maintain mobility and independence for years. PPMS can lead to physical disability, but how quickly or whether it develops looks different for everyone. Some people notice gradual changes, while others may stay stable for long stretches of time. Not everyone will need mobility aids like canes or wheelchairs, especially early on. A 2022 study found that about 10% of people with MS experience severe disability within 5 years of diagnosis. That number rises to 25% within 10 years and then increases to 50% after 18 years. Still, this doesn't mean you should expect disability after receiving a PPMS diagnosis. The location of lesions, your overall health, and how early you begin treatment can all play a role in how the condition progresses. Working with your doctor on a treatment plan that includes physical or occupational therapy and regular movement can help you stay active and independent for longer. Myth: Having PPMS means you have to quit your job Fact: Many people with PPMS continue working, sometimes with a few adjustments. A PPMS diagnosis doesn't automatically mean you need to stop working. While symptoms like fatigue, changes in memory or thinking, or mobility issues can make certain jobs more challenging, many people with PPMS continue in full- or part-time work, especially in the early stages. Everyone's experience with PPMS is different, so your ability to work will depend on your specific symptoms and the demands of your job. If you're facing obstacles, workplace accommodations, like flexible hours, assistive devices, or ergonomic adjustments, may help you stay on the job. A conversation with your doctor or a vocational (work) counselor who understands chronic conditions can also help you explore options that support your health and independence. Myth: No medications help PPMS, so you should investigate natural remedies Fact: There are FDA-approved medications that can help slow the progression of PPMS, including ocrelizumab. While some natural remedies might offer symptom relief, they aren't always safe or proven to be effective. For years, there were no FDA-approved treatments for PPMS. That changed in 2017 when Ocrevus (ocrelizumab) became the first medication approved specifically for PPMS. In a study of 732 people with PPMS, those who received Ocrevus experienced a slower rate of disability progression compared to those who received a placebo. It remains the only approved disease-modifying therapy for this form of MS. Doctors may also prescribe medications to manage specific symptoms, such as antidepressants for mood changes or muscle relaxants for spasms. Some people turn to natural remedies like herbal supplements, acupuncture, or cannabis. Research into these options is ongoing, but so far, there's no strong evidence that they're safe or effective for treating MS symptoms. Some supplements can even interact with prescription drugs. If you're considering natural treatments, talk with your doctor first to avoid potential side effects or interactions. Myth: PPMS is ultimately an isolating disease — no one will understand what you're going through Fact: You're not alone, and you don't have to go through it alone either. While PPMS can feel isolating at times, many others are navigating similar challenges. It's estimated that nearly 1 million people in the United States are living with MS, and about 10% to 15% of them have PPMS. Thanks to growing awareness and advocacy, there are now more resources and support networks than ever. Support groups, both in-person and online, offer a space to connect with others who understand what you're going through. If group support isn't for you, that's OK too. Talking with a trusted friend, loved one, or therapist can still help ease feelings of isolation and improve emotional well-being. What matters most is finding a form of support that feels right for you. Myth: PPMS is deadly Fact: PPMS is a lifelong condition, but it's rarely fatal. The progressive nature of PPMS and the fact that there's no cure can understandably lead to fears about long-term outcomes. But while PPMS can affect mobility, thinking, and daily functioning, it's not considered a life threatening illness. Most people with MS who don't have severe disabilities can expect to live another 30 to 35 years after diagnosis. Recent research has shown that even after significant disease progression, many people continue to live for years. For example, after someone loses the ability to walk independently, on average, at around age 51, life expectancy is about 13 more years. Advances in treatment, early intervention, and lifestyle changes can help manage symptoms, reduce complications, and support overall health. Taking care of your physical and emotional well-being through exercise, a balanced diet, regular checkups, and support can make a big difference in quality of life. It's important to note that with ongoing advances in treatment, the outlook for people with PPMS continues to improve. Current data on disability and life expectancy may not reflect what's possible in the future. Takeaway Misconceptions about primary progressive multiple sclerosis (PPMS) can add confusion and fear to an already complex condition. However, the reality is that PPMS doesn't always follow the path people expect. From treatment options to life expectancy, the facts paint a more hopeful and nuanced picture. While every experience with PPMS is different, understanding the reality behind the myths can help you make informed choices, find support, and feel more in control of your journey.
Business Wire
26 minutes ago
- Business Wire
AppLovin Investor Alert: Scott+Scott Attorneys at Law LLP Investigates AppLovin Corporation's Directors and Officers for Breach of Fiduciary Duties
NEW YORK--(BUSINESS WIRE)-- Scott+Scott Attorneys at Law LLP ('Scott+Scott'), an international securities and consumer rights litigation firm, is investigating whether the leadership of AppLovin Corporation ('AppLovin') (NASDAQ: APP) breached their fiduciary duties to AppLovin and its shareholders. Scott+Scott is investigating whether members of AppLovin's board of directors (the 'Board') made, or caused AppLovin to make, false and/or misleading statements, as well as failed to disclose material adverse facts, about AppLovin's business, operations, prospects, and financial health. Specifically, Scott+Scott is investigating whether the Board failed to disclose material information, including whether: (1) AppLovin is reverse-engineering and exploiting advertising data from Meta Platforms; (2) AppLovin is using manipulative practices to drive their own ad click-through and app download rates higher; (3) that, as a result, AppLovin was inflating installation numbers and thus its profit figures; and (4) as a result, statements about AppLovin's business, operations, and prospects lacked a reasonable basis. On February 26, 2025, two short reports were published, disclosing the above information. On this news, the stock price fell over 12.2%. What You Can Do – If you own shares of AppLovin, you may have legal claims against AppLovin's directors and officers. If you wish to discuss this investigation, or have questions about this notice or your legal rights, please contact attorney Joe Pettigrew toll-free at (844) 818-6982 or jpettigrew@ About Us Scott+Scott is an international law firm known for its expertise in representing corporate clients, institutional investors, businesses, and individuals harmed by anticompetitive conduct or other forms of wrongdoings, including securities law and shareholder violations. With more than 100 attorneys in nine offices in the United States, as well as three offices in Europe, our advocacy has resulted in significant monetary settlements on behalf of our clients, along with other forms of relief. Our highly experienced attorneys have been recognized for being among the top financial lawyers in 2024 by Lawdragon, WWL: Commercial Litigation 2024, and Legal 500 in Antitrust Civil Litigation, and have received top Chambers 2024 rankings. In addition, we have been recognized by the American Antitrust Institute for the successful litigation of high-stakes anticompetitive claims in the United States. To learn more about Scott+Scott, our attorneys, or complex case resolution, please visit Attorney Advertising
